REGISTER now for FREE 
|
FREE patent keyword monitoring and additional FREE benefits. REGISTER now for FREE
|
|
|
Drug, Bio-affecting And Body Treating Compositions > Designated Organic Active Ingredient Containing (doai) > Heterocyclic Carbon Compounds Containing A Hetero Ring Having Chalcogen (i.e., O,s,se Or Te) Or Nitrogen As The Only Ring Hetero Atoms Doai > Hetero Ring Is Six-membered And Includes At Least Nitrogen And Sulfur As Ring Members > Polycyclo Ring System Having The Six-membered Hetero Ring As One Of The Cyclos (e.g., 1,3- And 1,4- Benzothiazines, Etc.) > At Least Three Cyclos In The Polycyclo Ring System At Least Three Cyclos In The Polycyclo Ring SystemAt Least Three Cyclos In The Polycyclo Ring System patent applications listed are from June 2005 to current and include Date, Patent Application Number, Patent Title, Patent Abstract summary and are linked to the corresponding patent application page.11/16/06 - 20060258650 - Phenothiazine enantiomers as agents for the prevention of bone loss Disclosed is the unexpected finding that enantiomers of phenothiazines, preferably the (+) enantiomer of promethazine, are particularly effective in inhibiting the bone resorbing cells, osteoclasts, thus providing new uses and methods for reducing bone loss and, e.g., treating periodontitis and osteoporosis. The invention provides a range of such uses, methods, ... 10/12/06 - 20060229303 - Substituted quinobenzoxazine analogs and pharmaceutically acceptable salts, esters and prodrugs thereof; wherein A, U, V, W, X and Z are substituents. The present invention also relates to methods for using such compounds. ... 10/12/06 - 20060229302 - Tricyclic indole derivatives and their use in the treatment of alzheimer's disease The present invention to novel hydroxyethylamine compounds having Asp2 (β-secretase, BACE1 or Memapsin) inhibitory activit, processes for their preparation, to compositions containing them and to their use in the treatment of diseases characterised by elevated β-amyloid levels or β-amyloid deposits, Particularly Alzheimer's disease. ... 12/15/05 - 20050277633 - Spiro-rifamycin derivatives targeting rna polymerase Compounds of the current invention relate to rifamycin derivatives having antimicrobial activities, including activities against drug-resistant microorganisms. More specifically, compounds of the current invention relate to a series of novel spiro rifamycin derivatives which have demonstrated potent antimicrobial activity. ... 10/13/05 - 20050227971 - Thioamide derivatives as progesterone receptor modulators Thioamide compounds, and specifically, thioamide pyrrole compounds, and preparation thereof are provided. These thioamide compounds can be used as progesterone receptor modulators, in contraception, and in the treatment of progesterone-related maladies. ... 10/06/05 - 20050222139 - Non-peptide gnrh antagonists Compounds according to general formula 1, wherein A1-A3 are selected from A5 and A6 where A5 is either ═CR13— or ═N— and A6 is —NR14—, —O— or —S—; A4 is either a covalent bond or A5, provided that when A4 is a covalent bond one of A1-A3 must be A6 ... 09/15/05 - 20050203085 - Rifamycin c-11 oxime cyclo derivatives effective against drug-resistant microbes The current invention relates to a series of rifamycin derivatives having antimicrobial activities, including activities against drug-resistant microorganisms, specifically, the 3,4-cyclo-rifamycin derivatives having an oxime group at the C-11 position. ... 09/08/05 - 20050197333 - Rifamycin analogs and uses thereof The present invention features rifamycin analogs that can be used as therapeutics for treating or preventing a variety of microbial infections. In one form, the analogs are acetylated at the 25-position, as is rifamycin. In another form, the analogs are deacetylated at the 25-position. In yet other forms, benzoxazinorifamycin, benzthiazinorifamycin, ... 06/23/05 - 20050137189 - Rifamycin analogs and uses thereof The present invention features rifamycin analogs that can be used as therapeutics for treating or preventing a variety of microbial infections. In one form, the analogs are acetylated at the 25-position, as is rifamycin. In another form, the analogs are deacetylated at the 25-position. In yet other forms, benzoxazinorifamycin, benzthiazinorifamycin, ... ### FreshPatents.com Support |